Sphenopalatine Ganglion Block Study
Status and phase
Completed
Phase 1
Conditions
Sphenopalatine Ganglion Nerve Block
Treatments
Device: angiocatheter
Drug: Bupivacaine
Details and patient eligibility
About
The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question[s] it aims to answer are:
- Does a high dose (3ml) give more relief than a low dose (1ml)?
- Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed.
Researchers will compare dosage and administration to see how symptoms are reduced.
Enrollment
220 patients
Sex
All
Ages
18+ years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Present to ED for management of headache
- Headache is moderate or severe in intensity
Exclusion criteria
- Allergy to bupivacaine
- Nasal or sinus surgery
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
None (Open label)
220 participants in 4 patient groups
High dose with unilateral administration
Active Comparator group
Description:
High dose (3ml) with unilateral administration of bupivacaine
Treatment:
Drug: Bupivacaine
Device: angiocatheter
High dose with bilateral administration
Active Comparator group
Description:
High dose (3ml) with bilateral administration of bupivacaine
Treatment:
Drug: Bupivacaine
Device: angiocatheter
Low dose with unilateral administration
Active Comparator group
Description:
Low dose (1ml) with unilateral administration of bupivacaine
Treatment:
Drug: Bupivacaine
Device: angiocatheter
Low dose with bilateral administration
Active Comparator group
Description:
Low dose (1ml) with bilateral administration of bupivacaine
Treatment:
Drug: Bupivacaine
Device: angiocatheter
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems